Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
2.070
-0.035 (-1.66%)
At close: Nov 6, 2026, 4:00 PM EST
2.100
+0.030 (1.45%)
After-hours: Nov 6, 2026, 7:41 PM EST
Niagen Bioscience Stock Forecast
NAGE's stock price has decreased by -69.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 analysts polled by S&P Global, Niagen Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $11.75. The average 1-year stock price forecast is 467.63% higher than the current stock price, while the lowest is $8.50 (+310.63%) and the highest is $22 (+962.80%).
Price Target: $11.75 (+467.63%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +238.16% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $11 → $10 | Buy | Reiterates | $11 → $10 | +383.09% | Nov 4, 2026 |
| Roth MKM | Roth MKM | Buy Maintains $10 | Buy | Maintains | $10 | +383.09% | Oct 12, 2026 |
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +431.40% | Jul 21, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Buy Initiates $9 | Buy | Initiates | $9 | +334.78% | Jul 6, 2026 |
Financial Forecast
Revenue This Year
126.06M
from 129.42M
Decreased by -2.60%
Revenue Next Year
147.27M
from 126.06M
Increased by 16.83%
EPS This Year
n/a
from 0.17
Decreased by -100.00%
EPS Next Year
-0.06
EPS and Forward PE are based on non-GAAP adjusted numbers.